Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 11/20 | 0.39 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17817075 | 0.85 | SLC10A1 (0.54) | SLC10A1NR1H4GPBAR1PRKCDCES2 | |
| SCHEMBL17832964 | 0.85 | SLC10A1 (0.54) | SLC10A1NR1H4GPBAR1PRKCDCES2 | |
| SCHEMBL17832965 | 0.72 | SLC10A1 (0.60) | SLC10A1NR1H4GPBAR1PRKCD | |
| SCHEMBL17817298 | 0.72 | SLC10A1 (0.60) | SLC10A1NR1H4GPBAR1PRKCD | |
| SCHEMBL13384623 | 0.70 | SLC10A1 (0.73) | SLC10A1NR1H4GPBAR1PRKCDCES2 | |
| SCHEMBL476921 | 0.70 | SLC10A1 (0.73) | SLC10A1NR1H4GPBAR1PRKCDCES2 | |
| SCHEMBL13403268 | 0.70 | SLC10A1 (0.73) | SLC10A1NR1H4GPBAR1PRKCDCES2 | |
| SCHEMBL17817073 | 0.70 | SLC10A1 (0.55) | SLC10A1NR1H4GPBAR1PRKCDCES2 | |
| SCHEMBL476920 | 0.70 | SLC10A1 (0.73) | SLC10A1NR1H4GPBAR1PRKCDCES2 | |
| SCHEMBL13769854 | 0.70 | SLC10A1 (0.55) | SLC10A1NR1H4GPBAR1PRKCDCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021252290-A2 | COMPOSITIONS AND METHODS FOR TREATING NOVEL CORONAVIRUS SARS-COV-2-MEDIATED INFLAMMATORY CONDITIONS | GRI BIO, INC. (US) | 2021-12-16 | — | — | WO | disclosed |